Ionis Q2 Loss Widens on Launch Costs; Eplontersen Fails Key Trial
IONS sits 33% above its 52-week low of $40.03.
Summary
Ionis reported a Q2 2026 net loss of $114.6M as launch costs for TRYNGOLZA and DAWNZERA drove a 66% increase in SG&A. The Phase 3 failure of eplontersen in ATTR-CM removes a major pipeline opportunity, while collaboration milestones provided some offset.
Key Events · Earnings and Guidance · IONS
-
Q2 2026 Net Loss of $114.6M
Revenue declined 41% YoY to $267.9M, while operating expenses rose 19% to $370.2M, driven by a 66% surge in SG&A to $150.4M for the independent launches of TRYNGOLZA and DAWNZERA.
-
Eplontersen Phase 3 Failure in ATTR-CM
The CARDIO-TTRansform trial of eplontersen missed its primary composite endpoint of cardiovascular mortality and recurrent clinical events, a significant setback for the partnered pipeline.
-
Cash and Investments Decline to $2.1B
Cash, equivalents, and short-term investments fell from $2.7B at year-end 2025 to $2.1B, primarily due to the $432.5M repayment of the 0% convertible notes due 2026 at maturity.
-
Collaboration Milestones Provide Partial Offset
Ionis recognized $45M from Biogen for salanersen Phase 3 initiation, $21M from Recordati for the zilganersen license, and $20M from Ono for sapablursen Phase 3 initiation, among other payments.
Analysis · IONS · Life Sciences
A sharp swing to a $114.6M net loss in Q2 2026—from a $123.6M profit a year ago—underscores the heavy toll of Ionis's commercial transition. Revenue tumbled 41% to $267.9M while operating expenses climbed 19% to $370.2M, fueled by the costly independent launches of TRYNGOLZA and DAWNZERA, which pushed SG&A up 66%. Adding to the pressure, the Phase 3 CARDIO-TTRansform trial of partnered drug eplontersen in ATTR-CM missed its primary endpoint, a major pipeline blow that removes a key near-term catalyst. On the positive side, the company recorded multiple collaboration milestones, including $45M from Biogen for salanersen and a $21M license fee from Recordati for zilganersen. Cash and investments fell to $2.1B from $2.7B at year-end, largely due to the $432.5M repayment of maturing convertible notes. The quarter highlights the high cost of Ionis's evolution into a fully integrated commercial-stage company, now facing a significant pipeline setback.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $53.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $40.03 to $86.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.